Celularity vs MindWalk
CELU and HYFT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CELU and HYFT compare
MindWalk grew revenue faster over the last twelve months (43.4% versus −58.1% for Celularity).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CELU | HYFT |
|---|---|---|
| Size and price | ||
| Market cap | $20.4M | – |
| Share price | $0.630 | $0.990 |
| Change, 1 year | −62.5% | −44.7% |
| Change, 5 years | −99.1% | −82.1% |
| Beta (5Y) | 1.93 | 1.36 |
| Employees | 115 | – |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.1× | – |
| Growth | ||
| Revenue growth (TTM) | −58.1% | 43.4% (better) |
| Revenue growth, 5Y average | 13.2% (better) | −2.8% |
| Profitability | ||
| Gross margin | 19.2% | 60.8% (better) |
| Operating margin | −264% | – |
| Net margin | −246% | – |
| FCF margin | – | −76.9% |
| Financial health | ||
| Current ratio | 0.11 | 1.84 (better) |
| Altman Z-score | −16.48 | – |
| Piotroski F-score | 1 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 6.8% | 9.3% |
| Held by insiders | – | 0.00% |
Go deeper
- CELU stock overview
- CELU income statement
- CELU valuation and score
- HYFT stock overview
- HYFT income statement
- HYFT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.